Carmignac Gestion Makes New $469,000 Investment in Pfizer Inc. $PFE

Carmignac Gestion bought a new stake in Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 19,475 shares of the biopharmaceutical company’s stock, valued at approximately $469,000.

Other institutional investors have also added to or reduced their stakes in the company. Angeles Wealth Management LLC increased its position in shares of Pfizer by 2.2% during the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock valued at $410,000 after purchasing an additional 358 shares during the last quarter. Manchester Financial Inc. increased its stake in shares of Pfizer by 2.9% in the second quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 365 shares during the period. Vermillion Wealth Management Inc. raised its stake in shares of Pfizer by 19.4% during the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 382 shares during the last quarter. Eagle Capital Management LLC raised its position in Pfizer by 0.3% during the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after purchasing an additional 390 shares during the last quarter. Finally, Delta Financial Advisors LLC raised its holdings in shares of Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after acquiring an additional 398 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s recent rebound was supported by a quarterly earnings report that exceeded analyst expectations on both earnings and revenue, helping restore confidence in the beaten-down pharmaceutical stock. Why Pfizer Stock Was so Healthy in August
• Positive Sentiment: Commentary remains constructive on Pfizer’s approximately 6% dividend yield and the possibility that a strengthening drug pipeline could provide upside beyond income. One analyst cited a $32.72 12-month price target, implying potential appreciation from recent levels. Forget the Dividend: This Could Be the Real Reason to Buy Pfizer Stock Now
• Positive Sentiment: Novartis India agreed to acquire Pfizer brands for $132 million, including an established hypertension treatment. The transaction could provide cash and further streamline Pfizer’s portfolio toward higher-priority products, although its overall financial impact appears limited relative to Pfizer’s size. Novartis India Acquires Pfizer Brands for $132 Million
• Neutral Sentiment: CEO Albert Bourla is scheduled to discuss Pfizer at Morgan Stanley’s Global Healthcare Conference on September 14. Investors may look for updates on the pipeline, strategy, and outlook, but no new operating information was provided in the announcement. Pfizer Invites Public to Listen to Webcast
• Negative Sentiment: Pfizer’s high yield is attracting attention, but investors are being encouraged to choose AbbVie instead because of its stronger dividend-growth profile. This reinforces concerns that Pfizer may offer income today without comparable long-term dividend growth. Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now
• Negative Sentiment: Broader commentary describes Pfizer as still struggling and highlights uncertainty surrounding its post-COVID growth strategy and next-generation drug pipeline. These concerns can limit investor enthusiasm despite the earnings beat and attractive valuation. This Is What I’d Do With Pfizer Stock Right Now

Analyst Upgrades and Downgrades

Several analysts have commented on PFE shares. JPMorgan Chase & Co. lowered their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday. HSBC cut Pfizer from a “buy” rating to a “hold” rating and lowered their price objective for the company from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, BMO Capital Markets cut their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $28.28.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.67 during trading on Tuesday, reaching $27.78. 31,737,771 shares of the company traded hands, compared to its average volume of 41,536,398. The firm has a 50 day simple moving average of $26.06 and a 200-day simple moving average of $26.34. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $29.21. The stock has a market capitalization of $158.34 billion, a PE ratio of 36.55, a P/E/G ratio of 1.91 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were given a $0.43 dividend. The ex-dividend date was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. Pfizer’s dividend payout ratio is presently 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.